Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Algernon Pharmaceuticals (CSE: AGN | OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.

Watch the Video here.

CEO Clips – are short company video profiles broadcast to a large audience of investors on TV and 15+ financial sites including Reuters, Yahoo!Finance, and Wall Street Journal.